NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.69M | 3.82M | 3.84M | 3.53M | 3.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.32M | 6.47M | 6.29M | 5.79M | 5.01M |
| Operating Income | -6.32M | -6.47M | -6.29M | -5.79M | -5.01M |
| Income Before Tax | -6.38M | -6.54M | -6.32M | -5.80M | -5.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.38 | -6.54 | -6.32 | -5.80 | -5.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.38M | -6.54M | -6.32M | -5.80M | -5.04M |
| EBIT | -6.32M | -6.47M | -6.29M | -5.79M | -5.01M |
| EBITDA | -6.17M | -6.33M | -6.18M | -5.70M | -4.95M |
| EPS Basic | -0.08 | -0.09 | -0.09 | -0.09 | -0.08 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.06 | -0.05 | -0.05 |
| EPS Diluted | -0.08 | -0.09 | -0.09 | -0.09 | -0.08 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.06 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 314.52M | 298.31M | 284.25M | 269.70M | 252.63M |
| Average Diluted Shares Outstanding | 314.52M | 298.31M | 284.25M | 269.70M | 252.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |